Learn how Corona Remedies Ltd’s IPO performed, including subscription data, key dates, price band details, and steps to apply using ASBA or UPI.
Corona Remedies Ltd launched its IPO on 8 December 2025, aiming to strengthen its capital base and support strategic growth initiatives within India’s pharmaceutical sector. The company is engaged in the development and distribution of branded formulations across therapeutic categories such as cardiology, diabetology, dermatology, and pain management. With a well-established domestic presence, the IPO has garnered attention from investors seeking exposure to healthcare-driven opportunities. The public issue size stands at ₹655.37 Cr, offered through a book-building structure with defined pricing parameters.